Abstract

Macrophages (MPs) are heterogeneous, multifunctional, myeloid-derived leukocytes that are part of the innate immune system, playing wide-ranging critical roles in basic biological activities, including maintenance of tissue homeostasis involving clearance of microbial pathogens. Tumor-associated MPs (TAMs) are MPs with defined specific M2 phenotypes now known to play central roles in the pathophysiology of a wide spectrum of malignant neoplasms. Also, TAMs are often intrinsic cellular components of the essential tumor microenvironment (TME). In concert with lymphoid-lineage B and T cells at various developmental stages, TAMs can mediate enhanced tumor progression, often leading to poor clinical prognosis, at least partly through secretion of chemokines, cytokines, and various active proteases shown to stimulate tumor growth, angiogenesis, metastasis, and immunosuppression. Researchers recently showed that TAMs express certain key checkpoint-associated proteins [e.g., programmed cell death protein 1 (PD-1), programmed cell death-ligand 1 (PD-L1)] that appear to be involved in T-cell activation and that these proteins are targets of other specific checkpoint-blocking immunotherapies (anti-PD-1/PD-L1) currently part of new therapeutic paradigms for chemotherapy-resistant neoplasms. Although much is known about the wide spectrum and flexibility of MPs under many normal and neoplastic conditions, relatively little is known about the increasingly important interactions between MPs and B-lymphoid cells, particularly in the TME in patients with aggressive B-cell non-Hodgkin lymphoma (NHL-B). Normal and neoplastic lymphoid and myeloid cell/MP lineages appear to share many primitive cellular characteristics as well as transcriptional factor interactions in human and animal ontogenic studies. Such cells are capable of ectopic transcription factor-induced lineage reprogramming or transdifferentiation from early myeloid/monocytic lineages to later induce B-cell lymphomagenesis in experimental in vivo murine systems. Close cellular interactions between endogenous clonal neoplastic B cells and related aberrant myeloid precursor cells/MPs appear to be important interactive components of aggressive NHL-B that we discuss herein in the larger context of the putative role of B-cell/MP cellular lineage interactions involved in NHL-B pathophysiology during ensuing lymphoma development.

Highlights

  • Macrophages (MPs) are intrinsic end-stage immune myeloid cells that contribute to homeostasis as well as the body’s natural cellular immune and long-term inflammatory responses

  • We recently demonstrated that certain microenvironmental interactions involving cellular subsets of monocyte/MP lineage are necessary for long-term in vitro cell culture and pathological characterization of primary Mantle Cell Lymphoma (MCL) cells [70]

  • We recently discovered that culturing these primary MCL cells under hypoxic conditions enhances the activation of these Tumor-associated MPs (TAMs), increasing lymphoma cells’ viability and extending their survival

Read more

Summary

INTRODUCTION

Macrophages (MPs) are intrinsic end-stage immune myeloid cells that contribute to homeostasis as well as the body’s natural cellular immune and long-term inflammatory responses. Pleural effusions from patients with diffuse “histiocytic” lymphoma (currently known as DLBCL) were cultured in vitro, giving rise to an MP population with a wide variety of cellular functions, including promotion of lymphoma cell growth and survival, as well as inhibition of immune responsiveness. These studies demonstrated that lymphomaderived MPs differed markedly from normal peripheral blood donor-derived MPs, as the former could, for instance, induce formation of lymphocytic rosettes around tumor MPs. the functional significance of lymphocytic rosette formation was difficult to explain at that time, requiring additional probing into mechanisms that could underlie this phenomenon. Researchers in those studies primarily used key phenotypic markers such as CD68 and CD163 to detect TAMs, correlating marker expression patterns with clinical outcome in patients with different types of lymphoma [32, 33]

TAMs in HL Patients
TAMs in FL Patients
TAMs in DLBCL Patients
Derivation From Cells of Monocytic Lineage
Stimulation of Tumor Cell Growth and Survival
Provision of Chemoresistance Mechanisms to Cancer Cells
Findings
CONCLUDING REMARKS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call